HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

CBR 2092

structure in first source

Also Known As:

CBR-2092; CBR2092

Networked: 1 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinolines: 146
      - Quinolones: 2938
        CBR 2092: 1
  - 4 or More Rings Heterocyclic Compounds
    - Rifamycins: 416
      - CBR 2092: 1
Polycyclic Compounds: 6
- Macrocyclic Compounds: 15
  - Macrocyclic Lactams: 28
    - Rifamycins: 416
      - CBR 2092: 1

Experts

1.	Bonventre, Eric J: 1 article (07/2008)
2.	Doyle, Timothy B: 1 article (07/2008)
3.	Du, Qun: 1 article (07/2008)
4.	Duncan, Leonard: 1 article (07/2008)
5.	Lynch, A Simon: 1 article (07/2008)
6.	Morris, Timothy W: 1 article (07/2008)
7.	Robertson, Gregory T: 1 article (07/2008)
8.	Roche, Eric D: 1 article (07/2008)
9.	Yan, Dalai: 1 article (07/2008)

Related Diseases

1.

07/01/2008 - "Overall, CBR-2092 exhibited promising activity in a range of antimicrobial assays performed in vitro that pertain to properties relevant to the effective treatment of serious infections mediated by gram-positive cocci."
07/01/2008 - "We present data from antimicrobial assays performed in vitro that pertain to the potential clinical utility of a novel rifamycin-quinolone hybrid antibiotic, CBR-2092, for the treatment of infections mediated by gram-positive cocci. "

Related Drugs and Biologics

1.	Quinolones
2.	Rifamycins
3.	Anti-Bacterial Agents (Antibiotics)